Moderna Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 53.68
Dividend & YieldN/A$ (N/A)
Beta 1.73
Market capitalization 66.52B
Operating cash flow 6.63B
ESG Scores unknown

Company description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -50.24M -68M 3.85B 3.03B
Total Cashflows From Investing Activities -373.09M -15M -1.67B -8.52B
Net Borrowings 9.46M 1M -6M -140M
Total Cash From Financing Activities 1.23B 52M 2.03B -873M
Change To Operating Activities 6.83M 8M 156M 582M
Issuance Of Stock 564.45M 51M 2.04B 124M
Net Income -384.73M -514M -747M 12.2B
Change In Cash 522.88M -422M 2.39B 4.22B
Effect Of Exchange Rate
Total Cash From Operating Activities -330.87M -459M 2.03B 13.62B
Depreciation 24.86M 31M 93M 232M
Change To Account Receivables 832k 7M -1.39B -1.78B
Other Cashflows From Financing Activities
Change To Netincome 71.59M 77M 103M -122M
Capital Expenditures -105.77M -32M -68M -284M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -384.41M -515M -744M 13.29B
Net Income -384.73M -514M -747M 12.2B
Selling General Administrative 94.25M 110M 188M 567M
Gross Profit -319.01M -436M -575M 13.86B
Ebit -413.27M -546M -763M 13.3B
Operating Income -413.27M -546M -763M 13.3B
Interest Expense -3.1M -10M -10M -18M
Income Tax Expense 326k -1M 3M 1.08B
Total Revenue 135.07M 60M 803M 18.47B
Cost Of Revenue 454.08M 496M 1.38B 4.61B
Total Other Income ExpenseNet 28.86M 31M 19M -11M
Net Income From Continuing Ops -384.73M -514M -747M 12.2B
Net Income Applicable To Common Shares -401.86M -514M -747M 12.2B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 431.91M 414.61M 4.78B 10.52B
Total Stockholder Equity 1.53B 1.17B 2.56B 14.14B
Other Current Liabilities 124.61M 68.82M 3.87B 7.14B
Total Assets 1.96B 1.59B 7.34B 24.67B
Common Stock 33k 34k
Other Current Assets 595k 1.03M 228M 481M
Retained Earnings -1.01B -1.5B -2.24B 9.96B
Treasury Stock -1.32M 1.8M 3M -24M
Cash 658.36M 235.88M 2.62B 6.85B
Total Current Liabilities 222.8M 143.12M 4.39B 9.13B
Other Stockholder Equity -1.32M 1.8M 3M -24M
Property, Plant, and Equipment 211.98M 287.91M 387M 1.38B
Total Current Assets 1.56B 1.13B 6.3B 16.07B
Net Tangible Assets 1.53B 1.17B 2.56B 14.14B
Net Receivables 30.58M 16.3M 1.41B 3.3B
Accounts Payable 31.21M 7.09M 18M 302M


Insider Transactions

Here are the insider transactions of stock shares related to Moderna Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BANCEL STEPHANE JSale at price 175.01 - 178.13 per share.D/I2022-11-25Chief Executive Officer50k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-11-25Chief Executive Officer40k
AFEYAN NOUBAR BOGHOSSale at price 178.01 per share.D2022-11-23Director10k
BANCEL STEPHANE JSale at price 175.41 - 179.27 per share.D2022-11-23Chief Executive Officer40k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-11-23Chief Executive Officer40k
ANDRES JUANSale at price 178.01 per share.D2022-11-23Officer2k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-11-23Officer2k
BANCEL STEPHANE JSale at price 180.31 - 186.12 per share.D/I2022-11-17Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-11-17Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 184.25 per share.D2022-11-16Director10k
ANDRES JUANSale at price 184.25 per share.D2022-11-16Chief Technology Officer2k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-11-16Chief Technology Officer2k
BANCEL STEPHANE JSale at price 162.25 - 169.15 per share.D/I2022-11-10Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-11-10Chief Executive Officer80k
HOGE STEPHENSale at price 165.59 per share.D2022-11-10President231
ANDRES JUANSale at price 162.50 - 165.59 per share.D2022-11-10Chief Technology Officer2.19k
AFEYAN NOUBAR BOGHOSSale at price 162.50 per share.D2022-11-09Director10k
HOGE STEPHEND2022-11-09President522
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-11-09Chief Technology Officer2.44k
BURTON PAULSale at price 158.68 per share.D2022-11-07Officer192
BURTON PAULD2022-11-04Officer402
BANCEL STEPHANE JSale at price 138.61 - 154.89 per share.D/I2022-11-03Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-11-03Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 154.20 per share.D2022-11-02Director10k
ANDRES JUANSale at price 154.20 per share.D2022-11-02Chief Technology Officer2k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-11-02Chief Technology Officer2k
ANDRES JUANSale at price 150.00 per share.D2022-10-28Officer4k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-10-28Officer4k
BANCEL STEPHANE JSale at price 141.34 - 145.01 per share.D/I2022-10-27Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-27Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 137.25 per share.D2022-10-26Director10k
BANCEL STEPHANE JSale at price 118.98 - 128.73 per share.D/I2022-10-20Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-20Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 132.50 per share.D2022-10-19Director10k
BANCEL STEPHANE JSale at price 126.51 - 135.43 per share.D/I2022-10-13Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-13Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 135.36 per share.D2022-10-12Director10k
BANCEL STEPHANE JSale at price 122.40 - 126.31 per share.D/I2022-10-06Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-06Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 122.40 per share.D2022-10-05Director10k
BANCEL STEPHANE JSale at price 115.76 - 124.36 per share.D/I2022-09-29Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-29Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 123.58 per share.D2022-09-28Director10k
BANCEL STEPHANE JSale at price 124.20 - 131.44 per share.D/I2022-09-22Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-22Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 130.37 per share.D2022-09-21Director10k
BANCEL STEPHANE JSale at price 136.14 - 141.31 per share.D/I2022-09-15Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-15Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 134.00 per share.D2022-09-14Director10k
HOGE STEPHENSale at price 136.42 - 141.66 per share.D2022-09-13President6.97k
HOGE STEPHENConversion of Exercise of derivative security at price 10.90 per share.D2022-09-13President6.97k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Moderna Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Moderna Inc

Here is the result of two systematic investment strategies applied to Moderna Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Moderna Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Moderna Inc:

Moderna Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 941.78% on the backtest period.

Performance at glance

Performance

941.78 %

Latent gain

15550.78 $

Invested capital

1651.22 $

Annualized return

324.75 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Moderna Inc

This is the result of two momentum investment strategies applied to Moderna Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Moderna Inc

The following chart shows all the entries opened by the momentum investment system on Moderna Inc:

Moderna Inc momentum entries
  • The first momentum investment strategy would give 1500.3% of return on Moderna Inc. That represents 59267.01$ of latent gain with 3950.34$ of employed capital.
  • The second momentum investment strategy would give 1415.01% of return on Moderna Inc. That represents 26509.83$ of latent gain with 1873.47$ of employed capital.
Performance at glance (1Q Momentum)

Performance

1500.3 %

Latent gain

59267.01 $

Invested capital

3950.34 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

1415.01 %

Latent gain

26509.83 $

Invested capital

1873.47 $

Annualized return

584.71 %

Momentum equity curve on Moderna Inc

The following chart shows the equity curve of the two momentum strategies applied to Moderna Inc:

Moderna Inc momentum equity

Note: the dividends potentially given by Moderna Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Moderna Inc

The following chart shows the employed capital evolution of the two momentum strategies on Moderna Inc since the beginning:

Moderna Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Moderna Inc

Buy the dip entry openings on Moderna Inc

Moderna Inc

The performance achieved by the robo-advisor on Moderna Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Moderna Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Moderna Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Moderna Inc

The following chart shows the result of the investment strategy applied to Moderna Inc:

Moderna Inc

Note: the dividends potentially given by Moderna Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Moderna Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Moderna Inc:

Moderna Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Moderna Inc

In this section, I will compare the three previous investment strategies applied to Moderna Inc.

Equity curve comparison on Moderna Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Moderna Inc investment strategy comparison

Employed capital comparison on Moderna Inc

Moderna Inc investment comparison

Performance comparison on Moderna Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 941.78% 15550.78$ 1651.22$ 324.75%
Momentum 1 quarter 1500.3% 59267.01$ 3950.34$ 564.02%
Momentum 2 quarters 1415.01% 26509.83$ 1873.47$ 584.71%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

324.75 %

Momentum 1Q

584.71 %

Momentum 2Q

584.71 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Moderna Inc:

Positive correlations

Most correlated stocks this year

  • Moderna Inc

  • Most correlated stocks last 3 months

  • Moderna Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SATU HOLDINGS
  • SEEC MEDIA
  • One Stop Systems Inc
  • Trean Insurance Group Inc

  • Note: The algorithm computes the probability of correlation between Moderna Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Moderna Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Moderna Inc
    Country United States
    City Cambridge
    Address 200 Technology Square
    Phone 617 714 6500
    Website www.modernatx.com
    FullTime employees 3700
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker MRNA
    Market www.nasdaq.com

    Moderna Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown